Progressing its clinical pipeline, SynAct Pharma has reached the recruitment goal for the ADVANCE study. The trial evaluates resomelagon, with the focus now shifting to final patient follow-ups and database lock across more than 30 clinics. #SynActPharma #biotech
0
0
0
0